AlphAIAlphAI — Financial news for AI agents
investing.comNOV 41 min read$COR

Cencora Inc earnings beat by $0.09, revenue topped estimates

Cencora Inc (NYSE: COR) reported Q4 EPS of $4.66, beating estimates by $0.09, with revenue at $88.4B, exceeding expectations. The company forecasted FY 2026 EPS of $19.40-$19.75, higher than the consensus. Shares closed at $340.50, up 6.25% in 3 months but down 3.81% year-over-year.

Original reporting
investing.com
Published Nov 4, 2026, 11:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$COR
Bullish
high confidence
Mentioned
$COR
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CORBullishHigh
01

Why it matters

The earnings beat and guidance raise expectations for revenue growth, likely prompting buying interest.

02

Market read

Fresh earnings data for a large‑cap health‑care distributor, actionable for short‑term traders.

03

What to watch

Potential headwinds from upcoming generic competition and reimbursement pressures are not discussed.

Relevance 8/10Novelty 8/10Timing: post‑earnings release today

Background

Cencora Inc (NYSE: COR) is a major pharmaceutical distribution company. The article provides its Q4 earnings results and FY 2026 guidance.

Company-level read

Ticker impact

$CORBullishHigh confidence
Context

Cencora Inc reported Q4 EPS of $4.66, beating estimates by $0.09 and raised FY 2026 EPS guidance to $19.40‑$19.75.

Expected impact

likely upward pressure as the market prices in the earnings beat and higher guidance

Evidence & confidence

Both the surprise EPS beat and the upward revision of full‑year guidance are fresh, material data for a large‑cap pharma distributor.

Market effects

Sector

May lift peer drug distributors and contract manufacturers as earnings beat signals sector strength.

Regional

U.S. healthcare and pharma distribution stocks could see modest gains.

Global

Limited to U.S. markets; no immediate global macro effect.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face short‑term profit taking.

Key entities

  • company
    Cencora Inc

    Pharmaceutical distributor reporting earnings.

Read at source← All news

StoryCencora reports Q4 earnings beat and issues FY2027 EPS guidance

Also covered by

3 outlets

Related articles

NOV 4
$CORMed

Cencora, Inc. (COR): Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter Fourth Quarter Fiscal Year (As Revised) (As Revised)

Cencora, Inc. (COR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 CENCORA, INC. SUMMARY REPORTABLE SEGMENT INFORMATION (in thousands) (unaudited) The following illustrates revised reportable segment revenue information for the periods indicated: Fiscal Year Ended September 30, 2026 Revenue First Quarter Second Quarter Third Quarter

SEC EDGAR 8-K2 min
NOV 4
$CORHighAI 8/10

Cencora: Fiscal Q4 Earnings Snapshot

Cencora, Inc. (COR) reported fiscal Q4 earnings of $519.4 million, or $2.71 per share, beating analyst expectations. Revenue was $88.35 billion, also exceeding forecasts. The company expects full-year earnings of $19.40 to $19.75 per share.

finance.yahoo.com2 min
NOV 4
$CORHighAI 9/10

Cencora beats estimates on earnings and revenue

Cencora Inc. (NYSE:COR) reported Q4 adjusted EPS of $4.66, beating estimates, with revenue at $88.4B, up 5.5% YoY. The company issued fiscal 2027 EPS guidance of $19.40-$19.75, above consensus. Shares dipped 0.07% in pre-market trading. Cencora also raised its dividend by 10% and reaffirmed long-term growth targets.

investing.com2 min
NOV 4
$CORHighAI 8/10

CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS

Cencora, Inc. (COR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CENCORA REPORTS FISCAL 2026 FOURTH QUARTER AND FISCAL YEAR END RESULTS Fourth Quarter Revenue of $88.4 Billion up 5.5 Percent. GAAP Diluted EPS of $2.71 and Adjusted Diluted EPS of $4.66 Fiscal Year 2026 Revenue of $337.4 Billion up 5.0 Percent. GAAP Diluted EPS of $

SEC EDGAR 8-K2 min